吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Sep 12 2019

Full Issue

An FDA Quality-Control Nightmare With Carcinogen-Tainted Drugs Reveals Weak Spots In Federal Regulation System

The FDA has a rigorous approval process for new drugs--companies conduct clinical trials in humans over several years to prove a drug is safe and effective. But 90% of all medications prescribed to Americans are generics. They鈥檙e cheaper, they鈥檙e supposed to work the same way, and they receive less scrutiny right from the start. In other pharmaceutical news: a look at why there aren't better cancer drugs; the trouble with capping insulin prices; hidden secrets about a baldness drug; and more.

The chemical N-Nitrosodimethylamine, or NDMA, is a yellow liquid that dissolves in water. It doesn鈥檛 have an odor or much of a taste. It鈥檚 known to cause cancer in animals and is classified as a probable carcinogen in humans鈥攊t鈥檚 most toxic to the liver. A single dose of less than a milligram can mutate mice cells and stimulate tumors, and 2 grams can kill a person in days. An Oklahoma man poisoned the family of an ex-girlfriend in 1978 by pouring a small vial of NDMA into a pitcher of lemonade. In 2018 a graduate student in Canada sickened a colleague by injecting the chemical into his apple pie. (Edney, Berfield and Yu, 9/12)

Twenty years ago, the fight against cancer seemed as if it were about to take a dramatic turn. Traditionally, cancer doctors fought the disease with crude weapons, often simply poisoning fast-growing cells whether they were cancerous or healthy. But then a team of researchers hit on a new strategy: drugs targeting proteins produced by cancer cells that seemed necessary to their survival. (Zimmer, 9/11)

Jason Sheltzer thought he was learning answers to a simple question, but one that, for cancer patients, could mean the difference between life and death: Which genes can鈥檛 tumor cells survive without? Identifying DNA that seems essential to cancer cells鈥 survival tells drug developers which genes or gene products to target 鈥 a tried-and-true approach that has led to such lifesaving cancer drugs as Herceptin. (Begley, 9/11)

When Colorado earlier this year became the first state in the country to cap the price that some people will pay for insulin starting next year, skeptics questioned whether the change would raise insurance prices for everybody else. The answer, according to regulatory filings from insurance companies, is no. The Colorado Sun reviewed the documents that 21 health plans submitted to the state Division of Insurance to justify their proposed 2020 rates for the individual and small-group markets. Most plans didn鈥檛 mention the insulin caps at all as being a factor in their calculations. (Ingold, 9/11)

By the time Kelly Pfaff got home from driving her son to school that morning, it was too late. Her husband, John, was supposed to be taking their 4-year-old daughter to school. But the girl and the nanny were still at the Pfaffs鈥 house near San Diego. So were John鈥檚 wallet, cellphone and wedding ring. John was gone. (9/11)

Kaiser Health News: Congress Rakes In Millions From Drugmakers

Members of Congress raked in almost $4 million from pharmaceutical manufacturers and their trade groups in the first six months of 2019. Two members 鈥 Sen. Chris Coons (D-Del.) and Sen. Thom Tillis (R-N.C.) 鈥 each received over $100,000. Rep. Greg Walden (R-Ore.) is $5,000 shy of qualifying for the 鈥渕illion-dollar club,鈥 a group of current members who鈥檝e received $1 million or more since 2007. (Lucas, 9/12)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, August 7
  • Thursday, August 6
  • Wednesday, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF